Searchable abstracts of presentations at key conferences in endocrinology

ea0003p207 | Neuroendocrinology | BES2002

Measures of cardiovascular parameters in patients with acromegaly switched from SC octreotide to Sandostatin-LAR

Smith W , Oldroyd B , Belchetz P , Sivananthan M , Orme S

Studies have demonstrated an increased mortality in patients with acromegaly. The major cause of premature death was cardiovascular disease. Cardiovascular mortality was increased in patients with high levels of growth hormone (GH). Somatostatin analogues, such as octreotide, are effective in relieving the symptoms of acromegaly and supressing GH hypersecretion. Long acting preparations, such as Sandostatin-LAR, offer theoretical advantages over SC preparations, such as improv...